OUD Drug Pipeline: Buprenorphine & Naltrexone — PatSnap Eureka
Opioid Use Disorder Drug Pipeline: Long-Acting Buprenorphine, Naltrexone Depot & Novel Receptor Approaches
From approved PLGA-based depot formulations to preclinical D3R and orexin antagonists — explore the full OUD therapeutic pipeline powered by PatSnap patent and literature intelligence.
The OUD Pipeline: From Approved Depots to Preclinical Novel Targets
Retrieved patent and literature results identify eight distinct therapeutic modality clusters across the opioid use disorder pipeline, spanning approved long-acting formulations to early-stage receptor biology.
Subcutaneous Buprenorphine Depots & Implants
Three formulations dominate the approved landscape: CAM2038 (Buvidal®) for weekly/monthly dosing via atrigel-like polymer matrix; RBP-6000 (Sublocade™) using 18 wt% buprenorphine free base in 50:50 PLGA copolymer with NMP solvent; and Probuphine™ as a six-month subcutaneous implant. All eliminate daily supervision requirements and reduce diversion risk relative to sublingual formulations.
Indivior IP · EU + US ApprovedExtended-Release Naltrexone: Vivitrol® & Implants
XR-NTX (Vivitrol®, 380 mg IM monthly) achieves competitive MOR antagonism for an extended period, eliminating opioid reward and extinguishing reinforcement-driven relapse. Clinical data from six continents showed naltrexone implants achieved opioid-free lifestyle significantly more often than controls (adjusted OR = 6.00, 95% CI 3.86–9.50, P < 10⁻¹⁰). The Norwegian NaltRec study enrolled 150 patients for naturalistic monthly XR-NTX evaluation.
FDA Approved · AlkermesMethocinnamox (MCAM): Long-Acting MOR Antagonist
MCAM is a novel, highly potent MOR antagonist distinguished from naloxone and naltrexone by an extended duration of action. Preclinical data from Geisinger Commonwealth School of Medicine suggest dual-use potential: acute overdose rescue comparable to naloxone but longer-acting, and long-term OUD pharmacotherapy. No patent filings for MCAM were identified in this dataset, suggesting an open IP window for long-acting MOR antagonist formulation strategies.
Preclinical · Open IP WindowD3R, KOR, Orexin & PPAR: Beyond the MOR Axis
NIDA-IRP's (S)-ABS01-113 achieves 55% D3R efficacy at 7.6 ± 3.9 nM EC₅₀ — the most molecularly specific OUD-targeted compound in this dataset. KOR antagonist Opra Kappa (LY2456302) has reached human studies in cocaine dependence. Scripps Research Institute data positions orexin receptor blockade for prescription OUD. University of Toronto data covers PPAR-α/γ agonists including pioglitazone in preclinical addiction models.
NIDA-IRP · Rockefeller · ScrippsOUD Pipeline Data: Development Stages & Receptor Target Profiles
Key quantitative signals extracted from patent and literature analysis via PatSnap Eureka, covering clinical stage distribution and the pharmacological profile of leading novel receptor compounds.
OUD Pipeline: Development Stage by Modality
Long-acting buprenorphine and XR-NTX are the only approved modalities; all novel receptor targets remain preclinical or early clinical as of this dataset.
D3R Partial Agonist (S)-ABS01-113: Pharmacological Profile
NIDA-IRP's (S)-ABS01-113 achieves 55% D3R efficacy at 7.6 nM EC₅₀ — the most molecularly advanced non-opioid OUD compound in this dataset.
Naltrexone Implant Clinical Efficacy vs. Controls — Multi-Continent Data
University of Western Australia meta-analysis across six continents: naltrexone implants achieved opioid-free lifestyle significantly more often than controls (adjusted OR = 6.00, 95% CI 3.86–9.50, P < 10⁻¹⁰).
Key Molecular Targets Across the OUD Pipeline
The mu-opioid receptor (MOR/OPRM1) is the dominant target across all retrieved results. Buprenorphine's partial agonism provides a ceiling effect on respiratory depression while maintaining receptor occupancy sufficient to suppress withdrawal and craving. Retrieved results from Washington University in St. Louis describe a four-receptor endogenous opioid architecture — μ (MOPR), κ (KOPR), δ (DOPR), and nociceptin/orphanin FQ (NOPR) — each with distinct endogenous peptide ligands. The PatSnap life sciences platform enables systematic mapping of receptor-ligand patent landscapes across all four opioid receptor subtypes.
Chronic opioid exposure produces persistent upregulation of the constitutively active MOR-μ* conformer — proposed as a hallmark of opioid dependence by Ohio State University researchers. This has driven interest in biased antagonists: 6β-naltrexol (neutral antagonist) vs. naltrexone (inverse agonist) differ in their differential suppression of constitutive receptor signaling, suggesting pharmacological profile beyond simple antagonism could modulate dependence liability. According to NIH-affiliated research, G protein-biased vs. arrestin-biased signaling at MOR represents a key design rationale for next-generation OUD therapeutics.
A pharmacogenetic signal from Indivior-affiliated researchers identifies the OPRD1 rs678849 polymorphism in the delta-opioid receptor gene as a moderator of BUP-XR response across African American and European American cohorts (127 and 327 participants respectively in a 24-week study). This signals a precision medicine opportunity for patent landscape analytics in companion diagnostic development.
The KOR-dynorphin axis is consistently identified as a mediator of dysphoria, stress reactivity, and negative reinforcement in OUD. The orexin system (OX1R/OX2R) is implicated in motivation, arousal, and stress regulation — all relevant to OUD craving and relapse, per Scripps Research Institute data. NIDA research represents the most advanced publicly funded chemistry effort in the non-opioid OUD target space within this dataset.
Pipeline Strategy: IP Landscape & Translational Signals
Key strategic implications derived from patent and literature analysis across the OUD therapeutic pipeline.
Commercial IP Concentrated in Long-Acting BUP
Indivior UK Limited is the sole patent filer in this dataset, claiming PLGA-based sustained-release buprenorphine formulations (18 wt% BUP free base in 50:50 PLGA/NMP, IL jurisdiction, 2020). Competitive positioning in this space likely requires superiority in dose flexibility, patient-reported outcomes, or pharmacogenetic stratification rather than de novo MOA differentiation.
OPRD1 Pharmacogenetics: Precision Medicine Signal
The Indivior-linked clinical finding that OPRD1 rs678849 moderates BUP-XR response across racial populations (127 African American, 327 European American participants) signals a precision medicine opportunity — potential for companion diagnostic development or genotype-guided MOUD selection protocols in next-generation buprenorphine labeling.
Who Is Driving OUD Pipeline Innovation?
The innovation landscape in this dataset is predominantly literature-driven (academic research), with one commercial patent filing. Key institutions span US federal research, academic medical centers, and European institutions.
| Assignee / Institution | Country | Primary Contribution | Stage |
|---|---|---|---|
| Indivior UK Limited | UK/IL | PLGA-based BUP-XR patent (2020); pharmacogenetic BUP-XR clinical data (OPRD1 rs678849) | Commercial IP |
| Alkermes Inc. | US | XR-NTX (Vivitrol®) clinical research; samidorphan pharmacokinetics; BUP-to-XR-NTX transition trial (NCT02696434) | Approved |
| NIDA-IRP (National Institute on Drug Abuse) | US | D3R-selective (S)-ABS01-113 compound series (55% efficacy, 7.6 nM EC₅₀) | Preclinical |
| Rockefeller University | US | Opra Kappa (LY2456302) human study in cocaine dependence; endogenous opioid systems review | Early Clinical |
| UCLA / Center for Behavioral & Addiction Medicine | US | RECOVER study (NCT03604861): 12-month BUP-XR longitudinal outcomes, 35 US community sites | Post-Market |
| University of Western Australia | AU | Naltrexone implant meta-analysis: adjusted OR = 6.00 (95% CI 3.86–9.50, P < 10⁻¹⁰) | Clinical Evidence |
| Scripps Research Institute | US | Orexin receptor blockade for prescription OUD; motivation and stress regulation mechanisms | Preclinical |
Map the full OUD IP landscape with PatSnap Eureka
Identify patent white spaces, assignee activity, and clinical translation signals across every OUD modality using PatSnap Analytics.
Combination Approaches & Next-Generation OUD Strategies
Retrieved results signal several combination and augmentation directions layered onto existing approved pharmacotherapies, including digital therapeutics, precision pharmacogenomics, and adjunctive agents.
reSET-O + Buprenorphine: 3,144 Patient Real-World Dataset
Pear Therapeutics data describes reSET-O, an FDA-authorized prescription digital therapeutic (PDT), co-administered with buprenorphine MOUD. Real-world data from 3,144 patients showed engagement and substance use outcomes — signaling an emerging digital-pharmacological combination paradigm. This represents a near-term pipeline value vector beyond new molecules. Learn more about how innovators use PatSnap to track digital therapeutics IP.
3,144 real-world patients · FDA-authorizedBuprenorphine + Samidorphan (BUP/SAM)
Alkermes-affiliated data describes BUP/SAM as a strategy to achieve partial MOR agonism while providing antagonist coverage. A crossover human pharmacology study of BUP+samidorphan ratios in MDD patients with opioid experience indicates samidorphan has reached Phase II-equivalent human studies as an opioid receptor antagonist, with potential OUD applicability without addiction potential. According to FDA regulatory precedent, combination receptor strategies are increasingly evaluated for OUD labeling.
Phase II-equivalent · AlkermesAI & Transcriptomic Target Discovery for OUD
Two papers from University of Pittsburgh and a Department of Computational and Systems Biology group describe computational strategies using striatum transcriptomic data to identify novel molecular targets and repurposable compounds for opioid dependence — representing an emerging AI/computational frontier. PatSnap's open API enables integration of patent data with computational drug discovery workflows for target identification.
U Pittsburgh · Computational Systems BiologyUltra-Low-Dose Naltrexone & Pro-Dopamine Adjuncts
An Albert Einstein College of Medicine patent describes simultaneous enhancement of analgesic potency and attenuation of dependence liability through ultra-low-dose naltrexone co-administered with conventional opioids. Separately, multiple retrieved papers describe KB220 (glutaminergic-dopaminergic optimization nutraceutical complex) as an adjunct to naltrexone to improve adherence and dopamine reward circuitry restoration — a compliance enhancement strategy for naltrexone therapy. WHO guidelines increasingly recognize adherence as a primary OUD treatment outcome metric.
Albert Einstein Patent · KB220 adherence dataOUD Drug Pipeline — Key Questions Answered
Three specific formulations appear repeatedly in the evidence: CAM2038 (Buvidal®), a subcutaneous depot for weekly and monthly administration using an atrigel-like polymer matrix with European Commission approval and UK availability; RBP-6000 (Sublocade™), a monthly subcutaneous injection using 18 wt% buprenorphine free base in a 50:50 PLGA copolymer with NMP as solvent; and Probuphine™, a six-month subcutaneous implant delivering continuous buprenorphine.
The mechanism is competitive MOR antagonism: by blocking opioid receptors for an extended period, XR-NTX eliminates the rewarding effects of opioids, thereby extinguishing reinforcement-driven relapse. Clinical trial data from six continents demonstrated naltrexone implants achieved opioid-free lifestyle significantly more often than controls (adjusted OR = 6.00, 95% CI 3.86–9.50, P < 10⁻¹⁰).
Retrieved results identify the dopamine D3 receptor (D3R), kappa-opioid receptor (KOR/KOP-r), delta-opioid receptor (DOR/DOP), orexin receptors (OX1R/OX2R), peroxisome proliferator-activated receptors (PPAR-α and PPAR-γ), neurokinin receptors (NK1R), and DARPP-32 signaling as candidate therapeutic targets, though most remain at preclinical or early translational stages.
Methocinnamox (MCAM) is a novel, highly potent MOR antagonist distinguished from naloxone and naltrexone by an extended duration of action. Preclinical data suggest MCAM could serve dual purposes: acute overdose rescue (comparable to naloxone but longer-acting) and long-term OUD pharmacotherapy. No patent filings for MCAM were identified in this dataset, suggesting an open IP window for long-acting MOR antagonist formulation strategies.
Indivior-affiliated researchers report a completed 24-week clinical study (127 African American, 327 European American participants) demonstrating that OPRD1 rs678849 moderates BUP-XR therapeutic response — a precision medicine signal in the OUD space. This signals a potential for companion diagnostic development or genotype-guided MOUD selection protocols.
NIDA-IRP (National Institute on Drug Abuse Intramural Research Program) describes (S)-ABS01-113 as a highly D3R-selective and efficacious partial agonist (55% efficacy, EC₅₀ = 7.6 ± 3.9 nM) contrasted with its D3R-selective antagonist enantiomer (R)-ABS01-113. Both are structural analogs of (±)-VK4-40 with a 3-F substitution replacing the 3-OH. This represents one of the most molecularly specific OUD-targeted compounds in the retrieved dataset.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About OUD TargetsAccelerate Your OUD Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map therapeutic pipelines, identify IP white spaces, and track clinical translation signals across the opioid use disorder landscape.
References
- Recent advances in the treatment of opioid use disorders — focus on long-acting buprenorphine formulations — University of Applied Labour Studies, Mannheim, 2021 [Paper]
- Methods to treat opioid use disorder — Indivior UK Limited, 2020, IL [Patent]
- Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER — UCLA Department of Family Medicine, 2020 [Paper]
- Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management — University of Western Australia, 2012 [Paper]
- Naltrexone Implant for Opioid Use Disorder — University of Texas Southwestern, 2021 [Paper]
- Characteristics and treatment preferences of individuals with OUD seeking to transition from buprenorphine to extended-release naltrexone in a residential setting — Alkermes Inc., 2022 [Paper]
- A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder — NIDA Intramural Research Program, 2022 [Paper]
- Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis — Wake Forest School of Medicine, 2015 [Paper]
- Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management — Ohio State University, 2020 [Paper]
- Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence — Rockefeller University, 2017 [Paper]
- The Kappa Opioid Receptor: From Addiction to Depression, and Back — McGill University, 2014 [Paper]
- Targeting the Orexin System for Prescription Opioid Use Disorder — Scripps Research Institute, 2020 [Paper]
- Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders — University of Toronto, 2020 [Paper]
- The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review — Center for Pharmacy Innovation and Outcomes, 2022 [Paper]
- National Institutes of Health (NIH) — Research context: opioid receptor biology and NIDA-funded OUD programs
- National Institute on Drug Abuse (NIDA) — OUD epidemiology, treatment research, and D3R program context
- US Food and Drug Administration (FDA) — Regulatory approvals: Vivitrol®, Sublocade™, Probuphine™, reSET-O
- World Health Organization (WHO) — OUD treatment guidelines and adherence outcome frameworks
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.